Open AccessPotential role of marine species-derived bioactive agents in the management of SARS-CoV-2 infection
Author(s) -
Muhammad Asif,
Mohammad Saleem,
Hafiza Sidra Yaseen,
Ashwaq Hamid Salem Yehya,
Malik Saadullah,
Hafiz Muhammad Zubair,
Chern Ein Oon,
Pegah Moradi Khaniabadi,
Syed Haroon Khalid,
Ikram Ullah Khan,
. Mahrukh
Publication year - 2021
Publication title -
future microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.797
H-Index - 82
eISSN - 1746-0921
pISSN - 1746-0913
DOI - 10.2217/fmb-2021-0024
Subject(s) - covid-19 , pandemic , outbreak , biology , drug , drug discovery , clinical trial , in vivo , virology , in silico , medicine , pharmacology , computational biology , bioinformatics , infectious disease (medical specialty) , microbiology and biotechnology , pathology , biochemistry , disease , gene
COVID-19, caused by the SARS-CoV-2 outbreak, has resulted in a massive global health crisis. Bioactive molecules extracted or synthesized using starting material obtained from marine species, including griffithsin, plitidepsin and fingolimod are in clinical trials to evaluate their anti-SARS-CoV-2 and anti-HIV efficacies. The current review highlights the anti-SARS-CoV-2 potential of marine-derived phytochemicals explored using in silico , in vitro and in vivo models. The current literature suggests that these molecules have the potential to bind with various key drug targets of SARS-CoV-2. In addition, many of these agents have anti-inflammatory and immunomodulatory potentials and thus could play a role in the attenuation of COVID-19 complications. Overall, these agents may play a role in the management of COVID-19, but further preclinical and clinical studies are still required to establish their role in the mitigation of the current viral pandemic.